Efficacy and safety of azithromycin infusion in the treatment of mild/moderate community-acquired pneumonia

Efficacy and safety of azithromycin infusion in the treatment of mild/moderate community-acquired pneumonia - Efficacy and safety of azithromycin infusion in the treatment of mild/moderate community-acquired pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011836

Enrollment

100

Registered

2013-10-31

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with mild/moderate community-acquired pneumonia

Interventions

Azithromycin is given intravenously

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients 20 years of age and older 2.Patients with mild/moderate pneumonia according to the Japan Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults

Exclusion criteria

Exclusion criteria: 1.Patients with improving status receiving other treatments 2.Contraindication for asithromycin 3.Patients with cardiac disorders 4.Patients deemed ineligible by the attending physicians for various reasons

Design outcomes

Primary

Measure	Time frame
Efficacy and safety of azithromycin at the end of administration	—

Secondary

Measure	Time frame
1.Clinical efficacy 3 days after administration 2.Disappearance of main causative bacteria after azithromycin treatment	—

Countries

Japan

Contacts

Public ContactToshinori Kawanami

University of Occupational and Environmental Health, Japan Department of Respiratory Medicine

namihei@med.uoeh-u.ac.jp093-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026